Novartis today announced a five-year collaboration with the Big Data Institute (BDI) to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted. Using artificial intelligence (AI) and advanced analytics, the partners expect to transform how ultra large and multiple datasets are analysed, combined and interpreted to identify early predictors of patient responses to treatments for inflammatory diseases, such as multiple sclerosis (MS) and psoriasis.
Big Data Institute - Novartis partnership announced
22 January 2019
Novartis and the Big Data Institute establish world-leading research alliance using artificial intelligence to understand complex diseases and improve drug development.